Anixa Biosciences, Inc.
ANIX · NASDAQ
10/31/2024 | 10/31/2023 | 10/31/2022 | 10/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $2 | $0 |
| % Growth | -100% | -100% | 481,656.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $2 | $0 |
| % Margin | – | 23.3% | 100% | 24.9% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -5,243.3% | -0.6% | -2,563.1% |
| Other Income/Exp. Net | $0 | $0 | $0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -4,671.9% | -0.5% | -2,526.2% |
| EPS | -0.39 | -0.32 | -0.44 | -0.45 |
| % Growth | -21.9% | 27.3% | 2.2% | – |
| EPS Diluted | -0.39 | -0.32 | -0.44 | -0.45 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -5,221.4% | -0.6% | -2,552.4% |